title: Mitigating the cardiovascular risk of anemia in patients with type 2 diabetes and CKD: Does darbepoetin help? The TREAT Trial.
authors.affiliation: Department of Medicine, State University of New York-Downstate Medical Center and Kings County Hospital, Brooklyn, 11203, USA.
authors.forename: Christi
authors.initials: C
authors.lastname: Hayes
authors.forename: Anis
authors.initials: A
authors.lastname: Alam
authors.forename: Julie
authors.initials: J
authors.lastname: Black-Peart
authors.forename: Samy I
authors.initials: SI
authors.lastname: McFarlane
mesh_terms: D000740:Anemia / Q000150:complications* / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000150:complications*; D000068256:Darbepoetin alfa; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D004921:Erythropoietin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors
chemical_list: D004921:Erythropoietin; D000068256:Darbepoetin alfa